Skip to main content
. Author manuscript; available in PMC: 2021 Jul 7.
Published in final edited form as: Breast Cancer Res Treat. 2021 Apr 14;188(2):477–487. doi: 10.1007/s10549-021-06221-8

Table 3.

QOL point change at cycle 4 from baseline between Arm A and B

QOL Arm A Arm B p-value

n median (range) n median (range)
QOL overall 11 0 (−5, 1) 25 −1 (−6, 5) 0.26
Fatigue 11 1 (−3, 7) 25 0 (−4, 8) 0.75
Rash 10 0 (−4, 2) 25 0 (−5, 10) 0.095
Diarrhea 11 2 (−10, 8) 25 1 (−8, 8) 0.99
Hands and feet syndrome (skin or pain change) 11 2 (−1, 8) 25 4 (−7, 10) 0.42

Note: The positive value of QOL overall score represents better QOL after 4 cycles of treatment; the positive value of fatigue, rash, diarrhea, and hands and feet syndrome score represents worse syndrome at cycle 4. N represents sample size.